Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024

PALISADE BIO, INC.

PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.
In DSS-induced UC mouse model, significant reduction in disease activity index over time.
No CNS toxicity or emesis observed in dogs at effective doses.
Company advancing PALI-2108 toward Phase 1 clinical study, expected to start in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.